78 Biggest Movers From Yesterday
Gainers
Hycroft Mining Holding Corporation (NASDAQ: HYMC) shares jumped 138.1% to close at $1.50 on Thursday after dropping 37% on Wednesday.
Baird Initiates Coverage On TRACON Pharmaceuticals with Outperform Rating, Announces Price Target of $10
Baird analyst Joel Beatty initiates coverage on TRACON Pharmaceuticals (NASDAQ:TCON) with a Outperform rating and announces Price Target of $10.
4 Penny Stocks Insiders Are Buying: Ideanomics, Superior Industries And More
The IHS Markit composite PMI dipped to 50.8 in January 2022 from 57.0 a month ago, according to data released today. However, investors also focused on some insider trades in penny stocks.
5 Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
12 Health Care Stocks Moving In Wednesday’s After-Market Session
Gainers
Cognition Therapeutics (NASDAQ:CGTX) shares rose 14.9% to $6.62 during Wednesday's after-market session. The market value of their outstanding shares is at $145.8 million.
51 Biggest Movers From Yesterday
Gainers
Microbot Medical Inc. (NASDAQ: MBOT) shares climbed 65.1% to close at $8.95 on Monday after the company announced a strategic collaboration with Stryker Corporation to develop the LIBERTY robotic system for neurovascular applications.
Mid-Afternoon Market Update: Dow Surges Over 200 Points; Microbot Medical Shares Spike Higher
Toward the end of trading Monday, the Dow traded up 0.64% to 36,181.37 while the NASDAQ rose 1.19% to 15,838.88. The S&P also rose, gaining 1.07% to 4,776.31.
34 Stocks Moving In Monday’s Mid-Day Session
Gainers
Microbot Medical Inc. (NASDAQ: MBOT) shares jumped 69.6% to $9.19 after the company announced a strategic collaboration with Stryker Corporation to develop the LIBERTY robotic system for neurovascular applications.
TRACON Pharma’s Independent Data Monitoring Committee Recommends the Company Continue its ENVASARC Trial
TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics today announced the Independent Data Monitoring